- Home
- GITS vs ALZN Comparison
GITS vs ALZN Comparison
Compare GITS & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- ALZN
- Stock Information
- Founded
- GITS 2018
- ALZN 2016
- Country
- GITS South Korea
- ALZN United States
- Employees
- GITS N/A
- ALZN N/A
- Industry
- GITS
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- GITS
- ALZN Health Care
- Exchange
- GITS Nasdaq
- ALZN Nasdaq
- Market Cap
- GITS 4.8M
- ALZN 4.5M
- IPO Year
- GITS N/A
- ALZN 2021
- Fundamental
- Price
- GITS $1.46
- ALZN $3.40
- Analyst Decision
- GITS
- ALZN Strong Buy
- Analyst Count
- GITS 0
- ALZN 1
- Target Price
- GITS N/A
- ALZN $180.00
- AVG Volume (30 Days)
- GITS 54.2K
- ALZN 339.7K
- Earning Date
- GITS 07-15-2025
- ALZN 03-10-2025
- Dividend Yield
- GITS N/A
- ALZN N/A
- EPS Growth
- GITS N/A
- ALZN N/A
- EPS
- GITS N/A
- ALZN N/A
- Revenue
- GITS N/A
- ALZN N/A
- Revenue This Year
- GITS N/A
- ALZN $322.64
- Revenue Next Year
- GITS N/A
- ALZN N/A
- P/E Ratio
- GITS N/A
- ALZN N/A
- Revenue Growth
- GITS N/A
- ALZN N/A
- 52 Week Low
- GITS $0.10
- ALZN $0.63
- 52 Week High
- GITS $5.06
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- ALZN 26.43
- Support Level
- GITS N/A
- ALZN $4.59
- Resistance Level
- GITS N/A
- ALZN $6.12
- Average True Range (ATR)
- GITS 0.00
- ALZN 0.69
- MACD
- GITS 0.00
- ALZN -0.19
- Stochastic Oscillator
- GITS 0.00
- ALZN 10.05
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.